EUCTR2008-005232-33-FR进行中（未招募）1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Patient has given written informed consent before any trial-related activity is performed.
- •Patient is 18 years or older.
- •Planned for radical radiotherapy treatment and in whom neoadjuvant endocrine treatment is indicated.
- •Tumour, Nodule, and Metastatic (TNM) stage T2 (b or c)/T3/T4, N0, M0; or Gleason score = 7 or PSA = 10 ng/ml.
- •Eastern Co-operative Oncology Group (ECOG) score of ? 2.
- •Estimated life expectancy at least 30 months.
- •Prostate size > 30 cubic centimetres, measured by TRUS.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any previous treatment for prostate cancer.
- •Previous trans-urethral resection of the prostate.
- •Patients who are lymph node positive or have other metastatic disease.
- •Use of urethral catheter.
- •Is not considered a candidate for hormonal therapy as neoadjuvant treatment to radiotherapy.
- •Is currently treated with a 5-alpha reductase inhibitor. If the patient has been treated with a 5-alpha reductase inhibitor the treatment must have stopped at least 6 months prior to this study.
- •Is currently treated with an a-adrenoceptor antagonist. If the patient has been treated with an a-adrenoceptor antagonist the treatment must have stopped at least 8 weeks prior to this study.
- •History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
- •Hypersensitivity towards any component of the investigational products.
- •Previous history or presence of another malignancy, other than prostate cancer or treated squamous / basal cell carcinoma of the skin, within the last five years.
- •Has a corrected QT interval (using the Fridericia correction method) over 450 msec.
- •Has a history of or risk factors for Torsades de Pointes
- •At time of inclusion receive concomitant medications that might prolong the QT interval
- •A clinically significant disorder (other than prostate cancer) including, but not limited to, renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease, and alcohol or drug abuse or any other condition, which may affect the patient’s health or the outcome of the trial as judged by the Investigator.
- •Mental incapacity or language barrier precluding adequate understanding or co-operation.
- •Receipt of an investigational drug within the last 28 days proceeding screening or longer if considered to possibly influence the outcome of the current trial.
- •Previous participation in any degarelix trial.
研究者
相似试验
进行中（未招募）
1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate CancerEUCTR2008-005232-33-DEFerring Pharmaceuticals A/S240
进行中（未招募）
1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1 Level: PT Classification code 10060862 Term: Prostate cancerProstate CancerEUCTR2008-005232-33-GBFerring Pharmaceuticals A/S240
进行中（未招募）
不适用
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate CancerEUCTR2008-005232-33-NLFerring Pharmaceuticals A/S240
进行中（未招募）
不适用
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate CancerEUCTR2008-005232-33-GRFerring Pharmaceuticals A/S240
进行中（未招募）
不适用
A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of volume reduction of the prostate in patients with prostate cancer being candidates for medical castration - FE200486 CS31MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate cancerEUCTR2008-008604-40-PTFerring Pharmaceuticals A/S180